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Abstract: This paper sets out to explore the 
civil society organisations that engage in 
drug policy advocacy in Europe. Information 
was gathered through an Internet search 
carried out in English, French and Spanish, 
supplemented by data provided by national 
agencies in the 28 EU Member States, 
Norway and Turkey. Only organisations that 
had an Internet presence were included in 
the analysis. Of the 218 drug policy advocacy 
organisations identified, 71 % were found by 
the English language internet search, and 
48 % were located in countries where the 
search languages were the main language 
spoken. About 70 % of the organisations 
were active at national level, with the rest 
split almost equally between local or regional 
level and European or international level. 
The primary objectives of the organisations 
were predominantly in the area of practice 
development, with 26 % advocating 
use reduction and 39 % harm reduction 
approaches. Primary objectives in the field 
of legislative changes were pursued by the 
remainder, with 23 % in favour of control 
reduction and 12 % calling for control 
reinforcement. 
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I Summary 
In recent years, the profile and importance of advocacy 
organisations in the drugs area has increased. This change has 
been driven by a range of developments, including a greater 
number of formal mechanisms through which policymakers can 
be accessed and the increased ease of communication and 
information dissemination made possible through the Internet 
and other technologies. The result has been an expansion of 
possibilities for civil society to engage in advocacy in the drug 
policy area at national, European and international levels. In this 
context, the EMCDDA commissioned an exploratory mapping 
study of such advocacy organisations in Europe, the results of 
which are described in this paper.
Advocacy, both in the general sense and in the area of drug 
policy, can be defined in a variety of ways. This report adopts the 
definition provided by the Vienna NGO Committee on Narcotic 
Drugs, which defines advocacy as: ‘…activities and actions with 
the intention of influencing decision-makers and with the aim of 
developing, establishing or changing policies and practices and 
of establishing and sustaining programmes and services’. 
Three categories are used to describe the types of advocacy 
practiced in the drugs field. Self or peer advocacy is undertaken 
by individuals and peer groups speaking out for themselves, 
and is often associated with the rights-based agendas of 
disability and mental health activism. Professional advocacy 
is undertaken by ‘helping professions’ speaking on behalf of 
a person or an issue, often seeking the removal of structural 
barriers hindering their constituency’s needs being met. 
Public policy advocacy seeks to effect change mainly through 
legislation and resource allocation. The underlying consensus 
across these forms is of a transformative strategy for achieving 
social justice. An additional distinction can be drawn between 
case and cause advocacy, with case advocacy focusing on the 
needs of the individual and cause advocacy addressing social 
reform. In practice, however, advocacy stretches from one to the 
other. Advocacy also intersects the realms of lobbying, interest 
groups and social movements, in terms of their shared aims 
of influencing public policy and resource allocation decisions, 
legislation, or both, though by different approaches. 
Information about advocacy organisations in Europe was gathered 
through an Internet search carried out in English, French and 
Spanish, supplemented by data provided by the Reitox national 
focal points in the EU Member States, Turkey and Norway. For 
the purpose of the study, advocacy organisations were defined 
as organisations with a website-based Internet presence that 
contained a clearly stated aim to influence drug policy. 
Overall, 218 drug policy advocacy organisations with a live 
website presence were identified. The organisations identified 
were mainly based in pre-2004 EU Member States in the north 
and west of Europe. This result may reflect a bias introduced by 
the languages that were used in the Internet searches. Almost 
half of the organisations, (105, 48 %), were located in countries 
where the search languages were the main language spoken, 
namely the United Kingdom (18 %), Spain (14 %), France (11 %) 
and Ireland (5 %). Smaller clusters were located in Germany (6 %), 
Sweden (6 %) and Finland (5 %), with the remainder dispersed 
thinly among the other EU Member States and Norway. No 
advocacy organisations were identified in six countries: Cyprus, 
Estonia, Luxembourg, Malta, Slovakia and Turkey. 
The majority of advocacy organisations (69 %) operated on 
a national basis, less than one-fifth (17 %) had a local or 
regional remit and over one-tenth (14 %) had a European or 
international remit. 
Three main types of policy advocacy organisations were 
identified: civil society associations (32 %); NGOs or third 
sector organisations (32 %); and alliances, coalitions and 
networks of existing organisations (26 %). Smaller proportions 
of advocacy organisations were classified as professional 
or representative bodies (6 %), among which were medical 
unions and associations of lawyers or law enforcement officers, 
and user groups (5 %).
The most common tool used by organisations to influence drug 
discourses and disseminate information was some form of 
awareness raising activity (used by 82 % of the organisations), 
such as participating in media debates, providing commentary, 
or using social media such as blogs, Facebook and Twitter. 
More than half (52 %) of the advocacy organisations focused on 
lobbying at a national or EU–UN level, using policy submissions, 
petitions and participation in policy forums to bring attention 
to their issues of concern. Lobbying was used by organisations 
with divergent objectives. Education and training tools, such as 
seminars and conferences, were used by nearly half (45 %) of the 
advocacy organisations to share and disseminate information on 
their viewpoints. Almost a third (31 %) of the organisations sought 
to build and disseminate an evidence base through research 
and publications. Activist strategies, such as demonstrations 
and marches, were employed by a small proportion of advocacy 
organisations (11 %). A further small proportion of the drug 
policy advocacy organisations used legal advocacy to promote a 
human-rights based approach to drug policy (4 %).
Half of the organisations advocated on behalf of drug users 
(109, 50 %), with one-fifth of these (23, 21 %) advocating for 
cannabis users specifically, including medicinal cannabis 
users. Two-fifths of the organisations advocated for the benefit 
of society as a whole (89, 41 %), and these were largely 
engaged in public policy advocacy (55, 62 %). 
Overall, the main focus of the advocacy organisations identified 
in this study was on practice development and delivery (142, 
65 %). Over one-third of the organisations (39 %) advocated for 
a harm reduction ethos in drug services. A further one-quarter 
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(26 %) advocated for use reduction and a greater emphasis on 
prevention, abstinence and drug-free recovery. The remainder 
of the organisations focused on legislative reform, with almost 
one-quarter (23 %) seeking a reduction in drug controls and a 
liberalisation of drug policies ranging from decriminalisation, to 
regulation of consumption and legalisation. Just over one-
tenth of the organisations (12 %) advocated for more restrictive 
drug policies or control reinforcement.
Overall, almost half of the advocacy organisations (49 %) 
were involved in public policy (cause) advocacy, operating and 
campaigning at national or international level. One-third (35 %) 
were concerned with professional (case) advocacy, while the 
smallest grouping of advocacy organisations (17 %) conducted 
self or peer advocacy.
Organisations advocating for a reduction in drug controls 
focused on the perceived ineffectiveness of current global drug 
policy with regard to the crime, violence and corruption that 
it engendered. Harm reduction advocates were closely allied 
to those advocating control reduction through collaborative 
linkages, though the main focus of these groups was on access 
to services and service user involvement in decision making 
on their treatment from a rights-based perspective. Advocates 
of use reduction focused on drug education, prevention and 
abstinence or drug-free recovery. Organisations advocating 
drug control reinforcement sought a drug-free world and the 
eradication of drug use through education and law enforcement.
A small proportion of the public policy advocacy actors (9 %) 
sought to influence drug policy at a European or international 
level. Overall, the main advocacy orientation of these 
organisations, over one-third (37 %), was towards a reduction 
in drug controls, with about a quarter advocating for harm 
reduction (26 %) and a fifth for use reduction (21 %). The 
remaining 16 % called for the reinforcement of drug control 
legislation. These proportions differ from the orientation of 
advocacy organisations as a whole.
Organisations seeking to influence public policy at a European 
or international level used a similar set of advocacy tools. 
These tools included awareness raising, networking and 
knowledge exchange, lobbying, legal advocacy, education and 
training, and research to promote and support their cause. In 
terms of their constituency base, control reduction and harm 
reduction actors mainly advocated on behalf of people using 
drugs. Use reduction and control reinforcement organisations, 
on the other hand, mainly advocated on behalf of the wider 
society and, in particular, young people and families.
The organisations studied in this report are engaged in a 
process of targeted activities, aimed at influencing the attitudes 
and opinions of the public and policymakers on drug service 
provision, drug controls, or both. These processes were seen to 
be grounded in aspirations for an improvement in the well-being 
of the individuals, groups or societies affected by drug use.
Changes in the nature, methods and impact of advocacy in 
the drugs area are evolving against a backdrop of ongoing 
economic and financial problems in the European Union. As 
drug services and law enforcement agencies come under 
increased financial pressure, it is likely that the number and 
type of policy actors engaged in advocacy will grow. Equally, as 
communities affected by drug problems experience renewed 
difficulties in providing services, an increased impetus to 
engage in advocacy may emerge.
I  Introduction 
The drug policy area has always been influenced by a broad 
range of stakeholders. Historically, those engaged in advocacy 
have had an impact on a wide spectrum of drug policy issues, 
ranging from controls on the availability of opium, to the 
availability of interventions to reduce the harm from injecting 
drug use. In recent years, the profile and importance of 
advocacy organisations in the drugs area has increased. This 
change has been driven by a range of developments, including 
a greater number of formal mechanisms through which 
policymakers can be accessed and the increased ease of 
communication and information dissemination made possible 
through the Internet and other technologies. The result has 
been an expansion of possibilities for engaging in advocacy 
in the drug policy area at national, European and international 
levels. A wider range of individuals and organisations are now 
involved in campaigning on drug-related issues. They are 
actively engaging with policymakers to address areas where a 
need for change has been identified, ranging from the scope 
and content of drug policies and strategies, to the availability of 
specific measures and services. 
In this context, the EMCDDA commissioned an exploratory 
mapping study of such advocacy organisations in Europe, the 
results of which are described in this paper (1). The findings of 
this study provide the reader with an insight into drug policy 
advocacy organisations in Europe (2), and contribute to our 
understanding of policy actors in the drugs area. 
The following sections of this paper explain the meaning 
of advocacy in general and in the drugs area, and describe 
how the organisations discussed here were identified and 
classified. Key findings from the study are presented in three 
subsequent sections. These provide an analysis of the range, 
location, scope and type of advocacy organisations and their 
policy objectives and advocacy orientations, and go on to 
examine those organisations that operate at European and 
international levels. 
(1) This report is based on the results of a study undertaken for the emcdda by 
O’Gorman and moore, 2012, which can be accessed on the emcdda website.
(2) In this paper, drug policy advocacy organisations are referred to as advocacy 
organisations.
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I  Advocacy 
Because of the different forms it can take in practice and 
the variety of contexts that it takes place in, advocacy is 
understood in many different ways. This section of the report 
provides an introduction to the nature of advocacy in general 
and advocacy in the drug policy area specifically, which is 
informed by the literature review undertaken for this study.
I Meaning, application and theoretical basis
Advocacy (from the Latin advocare to summon, or call 
to one’s aid) is popularly understood as support for, or 
recommendation of, a particular cause or policy. At the core 
of this definition lies the notion of representation, which can 
take many forms. Self or peer advocacy is undertaken by 
individuals and peer groups speaking out for themselves, 
and is often associated with the rights-based agendas of 
disability and mental health activism. Professional advocacy 
is undertaken by ‘helping professions’ speaking on behalf of 
a person or an issue, often seeking the removal of structural 
barriers hindering their constituency’s needs being met. 
Public policy advocacy seeks to effect change mainly through 
legislation and resource allocation. The underlying consensus 
across these forms is of a transformative strategy for 
achieving social justice.
An additional distinction can be drawn between case and 
cause advocacy, with case advocacy focusing on the needs of 
the individual and cause advocacy addressing social reform. 
In practice, however, advocacy stretches from one to the 
other. Advocacy also intersects the realms of lobbying, interest 
groups and social movements, in terms of their shared aims 
of influencing public policy and resource allocation decisions, 
legislation, or both, though by different approaches. 
‘Insider strategies’, such as participating within official 
policy-making spaces by writing submissions or sitting on 
government committees and seeking to influence the policy-
making process, are favoured in advocacy work (Carbert, 
2004) over ‘outsider strategies’, such as demonstrations and 
street protests. Like social movements, advocacy groups can 
seek to change or maintain existing customs, norms and value 
systems, or, conversely, change attitudes, beliefs and laws, for 
example regarding drug control.
Overall, the advocacy movement is grounded in the belief that 
social change occurs through politics and that the state can 
be moved to act on behalf of people (Reid, 1999). Increasingly, 
this movement is seen to be grounded in a ‘theory of change’ 
paradigm, with specific strategies and interventions drawn 
from political science and used to effect the desired social 
change (Coffman et al., 2007; Stachowiak, 2007). 
Advocacy organisations have developed and grown in the 
expansion of ‘democratic spaces’ where civil society can 
participate in policy formation through, for example, formal 
mechanisms at local, national and international levels (see the 
box ‘What is civil society?’). These spaces facilitate dialogues 
between civil society and EU and other transnational governance 
bodies, with advocacy organisations seeking to influence policy, 
and national, EU and transnational bodies typically aiming to 
develop more inclusive and grounded policies. Overall, policy 
advocacy organisations and coalitions are seen to have had a 
long history of influence over public policy values and outputs, 
and as sites of active citizenship (Baumgartner and Leech, 1998; 
McConnell, 2010; Reisman et al., 2007).
While active civil society groups are seen to address 
what Hindess (2002) calls the ‘democratic deficit’ of the 
representative model of democracy, they have been criticised 
on the issue of representation and their legitimacy to act on 
behalf of an individual or group of ‘constituents’. However, 
Hammer et al. (2010) note that the advocacy community 
includes not only those organisations that represent others,
There are many different interpretations and definitions 
of the term ‘civil society’. In a broad sense, it can 
be regarded as the space between the economic 
marketplace and the state, where different associations 
operate. consequently, advocacy organisations are 
part of civil society and, in general, can be referred to 
as ‘civil society organisations’. In this report, we adopt 
the definition provided in the european commission’s 
green paper on civil society, which defines it as ‘…the 
associational life operating in the space between the 
state and market, including individual participation 
and the activities of non-governmental, voluntary and 
community organisations’ (european commission, 2006).
What is civil society? 
advocacy, both in the general sense and in the area 
of drug policy, can be defined in a variety of ways. This 
report adopts the definition provided by the Vienna NGO 
committee on Narcotic drugs, which defines advocacy as: 
‘…activities and actions with the intention of influencing 
decision-makers and with the aim of developing, 
establishing or changing policies and practices and of 
establishing and sustaining programmes and services’ (1). 
(1) see the website of the Vienna NGO committee on Narcotic drugs. 
What is advocacy? 
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but also beneficiaries, practitioners or those that engage in 
advocacy on the basis of insights gained from research, as well 
as activists motivated by ideals of social justice.
A number of contemporary trends have influenced the growth 
of policy advocacy. These include the shift towards more 
participatory forms of service delivery and governance at 
the local, national and European levels, and the expansion 
of philanthropic funding for advocacy work. In addition, the 
growth of electronic advocacy and social networking sites has 
provided a voice for drug users and rights-based campaigns.
I The historical context of drug policy advocacy
In many countries, advocacy organisations participate in 
drug policy discourses and the development of national drug 
strategies. The focus of such advocacy groups is shaped by the 
contexts in which they operate. These include the prevailing 
cultural norms on drug use, the jurisdictional control and 
regulation of drugs, and the type of welfare regime in operation, 
in terms of the policies, practices and services available for 
addressing drug use and drug-related harm. 
Since it became a defined area of public administration, 
drug policy has also been influenced by a range of different 
stakeholders. This has included different individuals, groups 
and organisations advocating on behalf of various interests of 
a personal, public and professional nature. Historically, calls 
for increased controls on drugs have come from religious, 
temperance and anti-opium movements, with regulation 
directed at economic interests in different industries, which 
themselves have been active in lobbying and campaigning. 
Similarly, professional interest groups, such as doctors, lawyers 
and scientists have been engaged in advocacy (Bruun et al., 
1975; Musto, 1999).
When the international drug control system was initially 
developing, under the League of Nations, non-governmental 
organisations (NGOs) were not afforded formal recognition 
in the League’s covenant. This changed, however, under the 
United Nations after the Second World War, where NGOs 
were given a statutory basis under the UN charter and allowed 
access to the Economic and Social Council (Bruun et al., 1975). 
Further mechanisms at the international and EU levels for the 
inclusion of advocacy organisations have emerged since then. 
The UN established the Vienna NGO committee (VNGOC) in 
1983, allowing access to the United Nations Office of Drugs 
and Crime and the Commission on Narcotic Drugs. Following 
a 2006 European Commission conference and green paper, 
the EU Civil Society Forum on Drugs was established in 2007, 
providing an arena for interaction between the Commission and 
civil society (Charlois, 2009; European Commission, 2006). Civil 
society is seen as playing an important role alongside other 
policy actors in informing EU drug policy and taking part in its 
coordination in the European Drugs Strategy 2013–20 (Council 
of the European Union, 2012). 
The level and scope of influence that can be exercised in these 
mainly consultative forums is, however, subject to certain 
limitations. For example, demand reduction and treatment 
issues receive more focus than supply reduction topics. 
Additionally, a broad range of civil society actors, lobbying 
from different standpoints, actively participate. This includes 
those campaigning for a ‘drug-free world’, for abstinence and 
prevention, for harm reduction and for drug control reform. 
As a result, the marketplace of ideas regarding drug policy is 
highly competitive, as divergent groups seek to influence the 
policy process.
I  Identifying and categorising  advocacy organisations
In order to identify and collect information on the different 
advocacy organisations operating in Europe, a systematic 
research method was developed and applied. The key steps in 
this approach, its limitations and the system used to classify 
advocacy organisations in Europe are described in this section 
of the report.
I Monitoring advocacy
The study was carried out between December 2011 and July 
2012, and consisted of a literature review, the development of 
a categorisation system for the advocacy organisations, the 
design of an Internet search method to collect the data, and 
the creation of a database to store the information and sort it 
for analysis.
The literature review was undertaken to inform the study as 
a whole and to develop a set of categories to differentiate 
between the types of advocacy organisations found. Data were 
collected from two main sources: the Reitox national focal 
points, which provided data on advocacy organisations in their 
countries (3); and a systematic Internet search for advocacy 
organisations (see the box ‘Internet search method’) that were 
based in any of the 28 EU Member States, Turkey or Norway.
(3) This information was collected as part of a wider qualitative data collection 
process for the emcdda in the drugs policy area. 
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Information about advocacy organisations in europe 
was mainly gathered through an Internet search. This 
was done by developing a search string, that is, a set 
of key words that yields the maximum number of 
relevant results when entered into a search engine. 
as the search was conducted in three widely spoken 
languages (english, French and spanish), two variations 
of the search string were used. at the outset, a number 
of exclusion criteria were defined to help focus the 
search and produce the most relevant results. advocacy 
organisations were defined as organisations with 
a website-based Internet presence that contained 
a clearly stated aim to influence drug policy. 
The national versions of the search engine Google were 
used to check each country for the presence of advocacy 
organisations. In doing so, the results generated by the 
search string were ‘sampled to exhaustion’. This process 
involved reviewing the first 100 links in the results 
and then continuing to assess subsequent links until 
20 successive links were irrelevant (emcdda, 2011; 
Hillebrand et al., 2010; solberg et al., 2011). 
step-by-step guidelines for the search were designed, 
which ensured consistency and made the technique 
replicable for repeat studies. after searching the Internet 
for relevant organisations, the ‘home’ and ‘about us’ 
sections of these websites were then reviewed in order to 
find the information needed to categorise the advocacy 
organisations. additional organisations were searched for 
in the ‘membership lists’ or ‘links’ pages of the websites. 
during this process, the information was collected in 
a data entry form and then entered into a database.
Internet search method 
Being an exploratory study, the research was subject to 
certain limitations. Advocacy organisations were defined as 
organisations with a clearly stated aim to influence drug policy 
on their website, which allowed the search to be consistent 
across countries. This excluded advocacy organisations 
without websites and those with a web presence based solely 
on social media sites. Organisations concerned with drug 
issues, but not explicitly established to influence drug policy 
were also excluded (4). Furthermore, the Internet searches 
were undertaken in English, French and Spanish. Additional 
organisations would have been located by a search using 
more languages.
(4) These included political parties, research centres, scientists, government 
advisory bodies, reitox national focal points, and HIV/aIds advocacy 
organisations that did not specifically advocate on behalf of drug users.
I Categorising advocacy organisations 
A number of recurring themes were identified during 
the literature review to enable the development of a set 
of categories covering the type of advocacy, the type of 
organisation, and the organisations’ advocacy objectives and 
orientations. These categories provided the basis for assessing 
the advocacy organisations identified though the Internet 
search. As a result, the organisations’ key characteristics 
could be recorded in a meaningful way, which facilitated this 
exploration and analysis of drug policy advocacy. 
Type of advocacy
Three categories were used to describe the type of advocacy 
that organisations were engaged in: peer, professional and 
public policy advocacy. 
Peer advocacy is characterised by the members of 
organisations sharing a common experience of drug use and 
associated harms, giving them a unique understanding of the 
issues and difficulties that can be experienced. Typically, these 
organisations include community-based groups, such as user-
groups, family or ethnic minority support groups, alongside 
community activist groups focused on specific places and 
issues, grassroots campaigns, voluntary civil society and 
faith-based groups. Collectively, these organisations are 
characterised by a low level of formal organisation and funding, 
and are involved in campaigning for service provision and 
support resources at a local or national level.
The practice of professional advocacy corresponds with 
many features of the idea of case advocacy, and is commonly 
undertaken by ‘operational’ NGOs, such as service providers 
and professional bodies, as well as non-peer groups. As 
a result of their front-line service contact with drug users, 
families and communities, these professional actors often 
focus on issues linked to practice and service provision. They 
are involved in policy advocacy primarily on behalf of, or with, 
drug-users and those affected by drug-related harms out of 
professional interests. 
Public policy advocacy organisations engage in what 
may be known as cause advocacy. This category includes 
‘campaigning’ NGOs, large-scale user-groups, grassroots 
networks, human rights or social justice organisations, 
policy research think-tanks and campaigning or lobbying 
organisations. They typically operate at the national and 
transnational levels.
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Type of organisation 
A wide range of organisations involved in drug policy advocacy, 
most of which are civil society organisations, were identified 
in the literature review and Internet search. Although the 
two terms are used interchangeably in the literature, a 
distinction was made here between civil society associations 
(voluntary, self-organised) and NGOs (legally structured and 
funded). Coalitions of existing organisations established 
to influence policy were allocated to an ‘alliance, coalition, 
network’ category. Groups that described their membership 
as consisting of drug users were allocated to a ‘user 
groups’ category, though these were often also civil society 
associations and could be part of a broader alliance. A final 
category, ‘professional or representative body’, was used to 
classify advocacy organisations that consisted of individuals 
whose work brings them into contact with drug-related 
problems, such as doctors, solicitors and law enforcement 
personnel. The organisations campaign for policy change.
In categorising such organisations, a degree of overlap is 
inevitably found. Organisations that could be classified in 
more than one category were assigned to the group they 
most closely resembled. The categories and their definition 
are given in Table 1.
Primary advocacy objectives and orientations
During the study, two distinct sets of objectives were identified 
within the drug policy advocacy field. For some organisations, 
the objective was in the area of practice development, in order 
to improve service responses, oriented either towards harm 
reduction or use reduction. Alternatively, the objective was 
legislative change and reform, oriented either towards control 
reduction or control reinforcement (see Table 2).
Table 2
Primary advocacy objectives and orientations of drug 
policy advocacy organisations
Objective Orientation Measures
Legislative  
change
control 
reinforcement
prohibition,  
increased restrictions
control reduction regulation, decriminalisation, 
legalisation
Practice 
development
Use reduction prevention, abstinence,  
drug-free recovery
Harm reduction public health harm and risk 
reduction interventions
Along with identifying the key characteristics of the advocacy 
organisations, this study sought to describe their main 
constituency base. Seven categories were identified. Namely, 
all drug users, cannabis users, the families of drug users, 
marginalised users, medicinal cannabis users, people living 
with HIV/AIDS and the wider society. In addition, the different 
advocacy tools being used by organisations were recorded. 
These included activism, awareness raising, education and 
training, legal advocacy, lobbying governments or transnational 
bodies such as the European Union and the United Nations, 
and research and publications.
The following section of this report presents the findings of this 
study using the categorisation described above.
I  Overview of advocacy  organisations in Europe
In this section, the findings on organisations engaged 
in drug policy advocacy are presented under the headings 
of location, scope of operation, type of organisation, 
advocacy tools, constituency base and policy objectives 
and orientations.
I  Number and location of drug policy  advocacy organisations
Overall, 218 drug policy advocacy organisations with a 
live website presence were identified through the Internet 
searches in English, French and Spanish and the information 
provided by the Reitox national focal points (see Table A2 in 
the Annex). The organisations identified were mainly based in 
pre-2004 EU Member States in the north and west of Europe. 
This result may reflect a bias towards those countries whose 
languages were used in the Internet searches. Almost half of 
the organisations, (105, 48 %), were located in countries where 
the search languages were the main language spoken, namely 
Table 1
Types of organisations involved in drug policy advocacy
Type Definition 
Alliance, coalition, 
network
multidisciplinary networks of organisations  
with common goals 
Civil society 
association 
Voluntary associations to advance common 
interests (parent, family support groups, 
community groups, grassroots), with little 
formal structure or funding, also including 
organisations which are self-funded or funded 
by philanthropists
NGO or third sector mainly not-for-profit service providers and 
campaigning advocacy organisations with 
a formal legal structure and funding 
Professional or 
representative body
Networks of peer professionals (doctors, lawyers, 
law enforcement personnel etc.), often acting in 
a representative capacity 
User group Organisations that describe their membership 
as consisting of drug users
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the United Kingdom (18 %), Spain (14 %), France (11 %) and 
Ireland (5 %). Smaller clusters were located in Germany (6 %), 
Sweden (6 %) and Finland (5 %), with the remainder dispersed 
thinly among the other EU Member States and Norway. No 
advocacy organisations were identified in six countries: 
Cyprus, Estonia, Luxembourg, Malta, Slovakia and Turkey (see 
Figure 1).
Three-quarters of the organisations’ websites (77 %, 167) 
were found through the Internet searches; of these, more 
than two-thirds were identified through the English language 
search (71 %), with 16 % being identified through the French 
language search and 13 % through the Spanish language 
search (Table 3).
Local knowledge of the advocacy arena played an important 
role in this study. This is evident from the Reitox national focal 
points’ identification of two-fifths (41 %) of the advocacy 
organisations that were located (Table 4). The data provided 
by the focal points helped compensate for the search bias 
introduced by the choice of languages.
Table 4 
Source of information on advocacy organisations
Number Percent
Internet search only 129 59
National focal points only 51 23
both Internet search and national 
focal points 
38 17
Total 218 100
I Scope of operation 
The majority of advocacy organisations (69 %) operated 
on a national basis, less than one-fifth (17 %) had a local 
or regional remit and over one-tenth (14 %) had a European 
or international remit (Table 5).
Examples of the types of advocacy organisations active at a local 
level included Rezidenti Na Skalce proti drogam (Na Skalce Street 
residents against drugs) in Prague, who campaigned against 
the operation of a low-threshold facility in the neighbourhood. 
In Ireland, the Ballymun Youth Action Project campaigned for a 
community response to the drug problems in their area. 
The majority of regional level advocacy organisations were 
based in Spain, reflecting the country’s system of government 
and administration, which is organised into regional 
autonomous communities (comunidad autónoma). Among 
Spain’s regional advocacy organisations are the supply control 
oriented network Fundación Galega Contra O Narcotrafico in 
Galicia and the Federacíon Andaluza ENLACE (Andalusian 
Federation of Drug Addiction and AIDS), a social justice and 
harm reduction support network. In Scandinavia, advocacy 
organisations tended to organise themselves on a regional 
basis across countries, such as the prohibition movement 
Norden Mot Narkotik (Nordic Countries Against Drugs). These 
organisations were also classified as being local or regional. 
The category European or international was reserved for 
organisations specifically seeking to influence policy at these 
levels. Not included in this category are organisations that, 
although having a strong European presence, operate at a 
level best defined as national: an example is the Hungarian 
Civil Liberties Union, which focuses primarily on Hungary and 
Central and Eastern Europe.
FIGUre 1:
Geographical distribution of advocacy organisations  
identified in the study
Number of organisations based in each country 
 0   1–5   6–10   11–15   >15  
Table 5
Scope of operation: number of advocacy organisations 
according to their primary level of operation
Number Percent
local or regional 37 17
National 151 69
european or international 30 14
Total 218 100
Table 3 
Advocacy organisations identified in the Internet search, 
by search language
Number Percent
english 119 71
French 27 16
spanish 21 13
Total 167 100
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I Type of organisation 
Three main types of policy advocacy organisations were 
identified: civil society associations (32 %); NGOs or third 
sector organisations (32 %); and alliances, coalitions and 
networks of existing organisations (26 %). Smaller proportions 
of advocacy organisations were classified as professional 
or representative bodies (6 %), among which were medical 
unions and associations of lawyers or law enforcement officers, 
and user groups (5 %) (Table 6).
In a general sense, all of the advocacy organisations fit under 
the rubric of civil society. However, within this domain lies 
a diverse collection of non-state, non-private, not-for-profit, 
third sector organisations that have different institutional 
capacities, structures and focuses. As outlined in the previous 
section, in order to assist the analysis, a distinction was made 
between these types of organisations. Advocacy organisations 
were designated as civil society associations if they were 
primarily voluntary in nature. Examples of such organisations 
include parent and family support groups (Parents Contre La 
Drogue, France), faith-based groups (Jesuit Centre for Faith 
and Justice, Ireland) and a range of cannabis activist groups 
such as the Hanfparade in Germany. Some overlap between 
cannabis activist groups and the ‘user groups’ category was 
unavoidable. In this study, only those advocacy organisations 
that explicitly declared their membership to be composed of 
‘users’ were categorised as user groups; an example is the 
Austrian Verein ‘Starke Süchtige’ — Association of ‘Strong 
Addicts’. It is possible, however, that the prevailing conditions 
in some countries may have discouraged organisations 
composed of users from revealing their use of drugs, and these 
would have been categorised as civil society organisations. 
NGOs or third sector organisations were typically larger than 
other advocacy organisations, and were legally constituted 
organisations with formal rules of operation and paid 
employees. These included operational NGOs with a service 
provision remit (La Huertecica, Spain), campaigning NGOs 
(Project Konoplja.org, Slovenia), development or human-rights 
advocates (the Drug Equality Alliance, United Kingdom), 
opinion shapers (the UK Drug Policy Commission, UKDPC), 
and NGOs with an international focus (Mainline, Netherlands).
In this study, alliances and coalitions were defined as 
multidisciplinary networks of existing organisations with 
common goals. For example, the Rome Consensus for a 
Humanitarian Drug Policy is a network of national Red Cross 
and Red Crescent societies which promotes a humanitarian 
drug policy. Actis, a Norwegian policy network on alcohol and 
drugs, is an umbrella organisation for voluntary organisations 
working in prevention, treatment and rehabilitation. 
Professional or representative bodies that promote the 
interests of their sectors or their clients included the Svenska 
Narkotika Polisföreningens Hemsidd (Swedish Narcotics 
Officers Association), made up of former and current law 
enforcement officers concerned with addressing drug-
related crime. In Denmark, the Gadejuristen (Street lawyers) 
organisation provided legal aid to marginalised drug users. 
The Polska Sieć Polityki Narkotykowej (Polish Network on Drug 
Policy) is a network of professionals working in the drugs field, 
which aims to protect the rights of drug users to treatment and 
promotes drug policy debate.
I Advocacy tools and constituency base
In the Internet searches, the main advocacy tools (to a maximum 
of three) used by each organisation were recorded (Table 7). 
The most common tool used by organisations to influence drug 
discourses and disseminate information was some form of 
awareness raising activity (used by 82 % of the organisations), 
such as participating in media debates, providing commentary, 
or using social media such as blogs, Facebook and Twitter.
More than half (52 %) of the advocacy organisations focused 
on lobbying at a national or EU–UN level, using policy 
submissions, petitions and participation in policy forums 
to bring attention to their issues of concern. Lobbying was 
used by organisations with divergent objectives, for example, 
the Associazione per la Cannabis Terapeutica (in Italy), 
which lobbied for the medicinal use of cannabis, and the 
Associação para um Portugal Livre de Drogas, which promoted 
opinions critical of harm reduction approaches and the 
decriminalisation of drugs in Portugal.
Table 6
Advocacy organisations classified by type of organisation
Number Percent
alliance, coalition or network 57 26
civil society association 69 31
NGO or third sector 69 32
professional or representative body 12 6
User group 11 5
Total 218 100
Table 7
Main advocacy tools used by advocacy organisations: 
number and percentage of the organisations found to use 
each tool
Number Percent
activism 22 11
awareness raising 179 82
education and training 99 45
legal advocacy 9 4
lobbying government or eU and UN 114 52
research and publications 68 31
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Education and training tools, such as seminars and 
conferences, were used by nearly half (45 %) of the advocacy 
organisations to share and disseminate information on their 
viewpoints. Among the organisations using this approach is 
Jeunesse Sans Drogue, a prevention oriented organisation 
working in schools and colleges in France. 
Almost a third (31 %) of the organisations sought to build 
and disseminate an evidence base through research and 
publications. Among the organisations adopting this approach 
were two in the United Kingdom: the Independent Scientific 
Committee on Drugs, founded to investigate and review the 
scientific evidence relating to drugs, and the Addiction Recovery 
Foundation, conducting research on drug-free recovery. 
Activist strategies, such as demonstrations and marches, were 
employed by a small proportion of advocacy organisations 
(11 %). These advocacy organisations were more akin to 
social movements, such as the different national groups 
organising annual global cannabis marches (for example, the 
Marcha Global da Marijuana Lisboa, KANABA in Poland and 
the Marche Mondiale du Cannabis, France). A further small 
proportion of the drug policy advocacy organisations used legal 
advocacy to promote a human-rights based approach to drug 
policy (4 %); an example is the International Centre on Human 
Rights and Drug Policy in the United Kingdom.
Half of the organisations advocated on behalf of drug users 
(109, 50 %), with one-fifth of these (23, 21 %) advocating for 
cannabis users specifically, including medicinal cannabis 
users. Two-fifths of the organisations advocated for the benefit 
of society as a whole (89, 41 %), and these were largely 
engaged in public policy advocacy (56, 62 %) (Table 8).
I Policy advocacy objectives and orientations 
Overall, the main focus of the advocacy organisations 
identified in this study was on practice development and 
delivery (142, 65 %). Over one-third of the organisations 
(39 %), the largest proportion, advocated for a harm reduction 
ethos in drug services. A further one-quarter (26 %) advocated 
for use reduction and a greater emphasis on prevention, 
abstinence and drug-free recovery. The remainder of the 
organisations focused on legislative reform, with almost 
one-quarter (23 %) seeking a reduction in drug controls and a 
liberalisation of drug policies ranging from decriminalisation, to 
regulation of consumption and legalisation. Just over one-
tenth of the organisations (12 %) advocated for more restrictive 
drug policies or control reinforcement (Table 9).
The levels of activity and orientations of drug policy advocacy 
organisations in Europe reflect a number of factors. These 
include the diversity of public attitudes and opinion towards 
drug use both within and between Member States, as well 
as the diversity of treatment practice and service provision 
available in the context of different models of welfare 
provision across Europe. In addition, they also reflect the 
level of drug control and enforcement policies in operation, 
particularly regarding cannabis consumption. For example, 
the largest proportion of organisations advocating reductions 
in drug controls were based in the United Kingdom (30 %), 
as were the largest proportion of organisations advocating 
harm reduction (24 %). The largest proportion of organisations 
advocating control reinforcement were based in Sweden 
(31 %), while no organisations advocating control reduction 
were identified there. Among those advocating use reduction, 
the largest proportion was located in Spain (28 %), although in 
that country there was a more mixed range of organisations, 
with some advocating for control reduction, control 
reinforcement or harm reduction. Even allowing for some bias 
in this study due to the small number of languages used in 
the Internet search, these findings indicate a geographical 
divide on drug policy positions across Europe (Table 10). The 
following section of this report explores the types of advocacy 
that organisations were engaged in and the characteristics of 
these advocacy types.
Table 8
Main constituency base of advocacy organisations
Number Percent
all drug users 76 35
cannabis users 21 10
Families of drug users 15 7
marginalised users 10 5
medicinal cannabis users 2 1
people living with HIV/aIds 5 2
Wider society 89 41
Total 218 100
Table 9
Primary objectives and orientations of drug policy  
advocacy organisations
Objective Orientation Number Percent
Legislative 
change
control reinforcement (prohibition, 
increased restrictions)
26 12
control reduction (regulation, 
decriminalisation, legalisation)
50 23
Practice 
development
Use reduction (prevention, 
abstinence, drug-free recovery)
57 26
Harm reduction (public health, 
harm and risk reduction)
85 39
Total 218 100
11 / 24
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Table 10 
Geographical distribution and policy orientation of advocacy organisations located in Europe
Country 
Control reduction Control reinforcement Harm reduction Use reduction
Number Percent Number Percent Number Percent Number Percent
Austria 1 2 2 2
Belgium 3 2 2 2 3 5
Bulgaria 2 8 2 2 2 4
Croatia 1 1
Czech Republic 4 8 3 12
Denmark 4 5
Finland 2 4 2 2 7 12
France 5 10 5 6 10 18
Germany 6 12 4 5 3 5
Greece 1 1 1 2
Hungary 3 6 2 2
Ireland 11 13
Italy 1 2 1 4 1 1  2
Latvia 1 1
Lithuania 3 4 2 4
Netherlands 4 8 2 2 1 2
Norway 2 8 1 1 1 2
Poland 1 2 2 2 1 2
Portugal 1 2 1 4 2 2
Romania 1 4 4 5 1 2
Slovenia 2 2 1 2
Spain 4 8 3 12 8 9 16 28
Sweden 8 31 2 2 2 4
United Kingdom 15 30 1 4 20 24 4 7
Non country specific 1 4 1 1 1 2
I  Exploring the forms of advocacy organisations in Europe
The data collected about advocacy organisations for this study 
revealed a range of targeted activities undertaken with a view 
to influencing the attitudes and opinions of the public and 
policymakers. Such action is aimed at changing or maintaining 
the ethos and availability of service provision, national and 
international drug controls, or both. These advocacy processes 
are rooted in the aspiration that the desired outcome would 
improve the well-being of individuals, groups or societies 
affected by drug use. This section explores the different forms of 
advocacy engaged in by the organisations observed in this study 
(see also Table A1 in the Annex).
I The nature of drug policy advocacy 
Advocacy has emerged within civil society as a mechanism for 
‘having voice’, particularly by, and on behalf of, marginalised 
and excluded groups or causes. However, rather than being 
a generic phenomenon, the literature review for this study 
revealed a distinction between different types of advocacy 
based on the social relationship and social distance between 
the advocate and the person or cause they are advocating 
for. This distinction, characterised by peer, professional and 
public policy advocacy provides the framework for analysis of 
advocacy organisations and their activities presented here.
Overall, almost half of the advocacy organisations (49 %) 
were involved in public policy (cause) advocacy, operating and 
campaigning at national or international level. One-third (35 %) 
were concerned with professional (case) advocacy, while the 
smallest grouping of advocacy organisations (17 %) conducted 
self or peer advocacy (Table 11). 
Table 11
Advocacy organisations classified by type of advocacy
Number Percent
peer 36 16
professional (case) 76 35
public policy (cause) 106 49
Total 218 100
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I Peer drug advocacy organisations 
Self or peer advocacy is characterised by people speaking out 
for, representing the interests of, or defending the rights of 
themselves or their peers. In the drugs field, this was the least 
common type of advocacy work identified (17 %). However, 
these groups may not necessarily use a public ‘shop-front’ 
such as a website to promote their views, and may be under-
represented in this study. Nonetheless, within this group, 
certain trends may be observed. 
Over half (58 %) of the peer advocacy organisations were 
civil society associations, that is, mainly voluntary and  
self-help groups with a shared experience of drug use and 
drug-related harms. In France, for example, this included 
Keep-Smiling, a voluntary organisation providing risk reduction 
information at music festivals. One-fifth (19 %) of the peer 
advocacy organisations were user groups, such as the Danish 
Bruger Foreninger (Drug Users Union). A slightly smaller 
number (14 %) were alliances, such as the Citywide Drug 
Crisis Campaign in Ireland, a network of community-based 
organisations. 
The majority of the peer advocates (two-thirds, 67 %) were 
organised on a national level, while a substantial proportion 
operated on a local or regional basis (25 %). Only a small 
number, such as the International Network of People who Use 
Drugs (INPUD), had the capacity to operate at a European or 
international level. 
Peer advocacy organisations were mainly involved in 
awareness raising activities (92 %), lobbying (44 %) and 
education and training (44 %). Although the level of activism 
was low among advocacy organisations in general, peer 
advocates were more likely to use activist tools than were 
professional or public policy advocacy groups. For example, 
Act Up-Paris, an organisation for people living with HIV/AIDS, tries 
to garner support for drug consumption rooms, harm reduction 
and legalisation of cannabis by using public demonstrations 
and campaigns.  
Seventy percent of the peer advocacy organisations 
represented the interests of either drug users (39 %) or 
the families of drug users (31 %). The largest proportion of 
peer organisations advocated for harm reduction services 
(44 %). Sizeable proportions were concerned with prevention, 
abstinence and drug-free recovery services (25 %) and 
the liberalisation of controls on drug use (22 %). Few peer 
advocacy organisations sought increased controls on drug  
use (8 %), and these were predominantly family support 
groups — such as Plovdiv (Mothers Against Drugs 
Association) in Bulgaria. 
I Professional drug advocacy organisations
Professional or ‘case’ advocacy is characterised by 
organisations speaking on behalf of specific persons or 
groups, often ones not in a position to do so independently. 
In the drugs field, the illicit nature of drug use and the stigma 
often attached to it would suggest that professional advocacy 
is a common practice to ensure that needs are met and 
entitlements to services are secured. Consequently, these 
professional-actors tend to have front-line service contact 
with drug-users, families and communities, and focus more on 
treatment practice and service provision. One-third (34 %) of 
the advocacy organisations identified in this study undertook 
such professional advocacy work. 
More than half (57 %) of these advocacy organisations were 
operational NGOs that were independent of the state, although 
often in receipt of public funding, and involved in service 
provision. These included, for example, Proyecto Hombre, an 
influential therapeutic community in Spain and Turning Point, a 
nationwide public health and social care provider in the United 
Kingdom. Over a quarter (29 %) were alliances or networks, 
such as the RFHL (National Association for Aid to Drug 
Abusers) in Sweden, a federation of associations and citizens 
critical of current Swedish drug policy and campaigning for a 
public health approach to addiction. Only 1 % of professional 
advocates were user groups, such as the Methadone Alliance 
in the United Kingdom, a user-led harm reduction organisation 
providing advocacy, training and helpline services. Almost 
half of the professional advocates represented drug users 
(47 %), while over one-third (37 %) of them acted on behalf 
of the wider society. None of these organisations advocated 
specifically on behalf of cannabis (including medicinal 
cannabis) users. 
Professional advocacy organisations were mainly focused on 
influencing national policies (71 %). An example is APDES in 
Spain, which seeks to reduce the risks associated with drug 
use and sex work. These organisations used an almost equal 
mix of awareness raising (66 %), education and training (61 %) 
and lobbying (57 %) to try to influence policies. A sizeable 
proportion (40 %) also used research evidence to substantiate 
their claims, such as the Scottish Drugs Forum in the 
United Kingdom and EUROPAD (European Opiate Addiction 
Treatment Association) in Italy. 
These advocacy organisations were mainly oriented towards 
service and practice development, rather than drug controls. The 
majority (63 %) advocated for a harm reduction approach; an 
example is DIA+LOGS in Latvia, a resource centre campaigning 
for the development and operation of a low-threshold centre for 
people living with HIV/AIDS and at-risk drug users. A smaller 
number advocated for a prevention or drug-free recovery 
approach (36 %); an example of these organisations is the 
European Federation of Therapeutic Communities, which is 
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based in Belgium and operates at the European and international 
levels. However, the distinction between harm reduction and 
prevention or abstinence approaches was less marked in some 
counties. In Spain, for example, organisations advocating harm 
reduction generally also championed prevention and drug-free 
recovery, as in the case of the Fundación Atenea Grupo GID 
organisation, which works on prevention and social reintegration 
programmes as well as providing an opioid substitution service.
I Public policy drug advocacy organisations
Public policy or ‘cause’ advocacy represents the interests 
of, or defends the rights of, a group of people or the general 
public. These advocacy organisations are mainly concerned 
with establishing rights or entitlements, promoting or resisting 
legislative or policy change, and are strongly influenced by 
ideals of social justice.
In the drugs area, public policy advocacy is largely undertaken 
by civil society associations (45 %), such as the Asociación 
Cannabica Valenciana in Spain, which campaigns for the 
normalisation of cannabis use. It is also undertaken by NGOs 
(22 %), like Project Konoplja, a pro-harm reduction organisation 
in Slovenia, which aims to inform people about cannabis. 
Coalitions, networks and alliances are also involved in this type 
of advocacy (28 %), such as the Nordic Alcohol and Drug Policy 
Network (NORDAN), in Finland, which campaigns for a restrictive 
drugs and alcohol policy. Although these organisations have 
a predominantly national focus (70 %), a higher proportion of 
them operate at an international or European level (18 % in total) 
compared to peer and professional advocates. 
Public policy advocates mainly carry out awareness-raising 
activities (91 %), in different media forms, to promote debate 
and discussion on their cause; an example is Huumeboikotti, 
a prevention oriented civil society association in Finland. 
Just over half (52 %) use lobbying tactics at a national and 
international level (see next section). Education and training 
tools and research evidence are used by similar proportions 
(35 % each). Over half (52 %) of the public policy advocates 
act on behalf of society at large, while a further substantial 
proportion represent the cause of drug users (25 %), and 
cannabis users specifically (18 %). 
The largest proportion of public policy advocates — two-
fifths (40 %) — campaign for a reduction in drug controls. 
This ranges from decriminalisation and regulation, as in the 
case of the UK-based Release, to legalisation, as promoted 
by Legalizace.cz, a cannabis campaigning organisation in 
the Czech Republic. Similar proportions (one-fifth each) of 
these organisations advocate for a prevention or abstinence 
approach, drug control reinforcement and harm reduction.
I  Advocacy organisations operating at the European or international level
The public policy drug advocacy organisations that operate at 
the European and international levels tend to have a greater 
degree of visibility than those campaigning at the national level. 
Looking at the specific patterns and trends present in this group 
of organisations further informs our overall understanding of 
drug policy advocacy. It is important to note that a number of 
drug public policy advocacy organisations with a presence and a 
voice in Europe and internationally do not fall within the scope of 
this study as they are not based in Europe (5). This section of the 
report explores the variety and scope of the different advocacy 
organisations operating at the European or international level. 
Just a small proportion of the public policy advocacy actors (9 %) 
sought to influence drug policy at a European or international 
level (Table 12). This small group of organisations is, nonetheless, 
influential in placing issues on the drug policy agenda.
Table 12
European and international public policy advocacy 
organisations, classified by advocacy orientation
Advocacy orientation
(number of 
organisations  
and percentage)
Organisation
Control reduction
(7, 37 %) 
beckley Foundation
eNcOd (european coalition for Just  
and effective drug policies)
european drug policy Initiative (edpI)
International centre on Human rights  
and drug policy
International drug policy consortium (Idpc)
Transform drug policy Foundation 
Transnational Institute (drugs and democracy)
Harm reduction
(5, 26 %)
correlation Network
diogenis (drug policy dialogue  
in south east europe)
eurasian Harm reduction Network (eHrN)
euro HrN (european Harm reduction Network)
Harm reduction International (HrI)
Use reduction
(4, 21 %)
dianova International
eUrad (europe against drugs)
Fad (Fundación de ayuda contra la 
drogadicción)
FdFe (Foundation for a drug-Free europe)
Control reinforcement
(3, 16 %)
european cities against drugs (ecad)
IOGT International
World Federation against drugs (WFad)
Total 19
(5) examples include: the Global commission on drugs policy, in brazil; the drug 
policy alliance and the drug Free america Foundation, Inc, both in the Us.
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These advocacy organisations operate from different spaces 
along a continuum of advocacy orientation. At one end of this 
range are organisations calling for a reduction in drug controls 
and the decriminalisation and regulation of drug use (mainly 
cannabis), such as Transform Drug Policy Foundation. On the 
other end are control reinforcement advocates seeking a drug-
free world, like European Cities Against Drugs.
Overall, the main advocacy orientation of these organisations, 
over one-third (37 %), was towards a reduction in drug controls, 
with about a quarter advocating for harm reduction (26 %) and 
a fifth for use reduction (21 %). The remaining 16 % called for 
the reinforcement of drug control legislation. These proportions 
differ from the orientation of advocacy organisations as a 
whole, where the primary concern was with harm reduction 
(39 %), followed by use reduction (26 %), control reduction 
(23 %) and control reinforcement (12 %). This reflects the focus 
of public policy advocacy in general and the current focus 
of discourses on drug control reform at both European and 
international levels.
These policy actors, though advocating for different objectives, 
share a number of similarities in terms of their advocacy 
practice, tools and constituency base. For example, all of 
these organisations used a similar set of advocacy tools, 
though to different effect. These consisted of awareness 
raising, networking and knowledge exchange, lobbying, legal 
advocacy, education and training, and research to promote 
and support their cause. 
Awareness raising tools were used to influence the attitudes 
and beliefs of both the public and policymakers, as well as to 
develop drug policy discourses in line with the standpoint of 
the organisation. A number of different forms of awareness 
raising were employed. These included participating in 
media debates, monitoring and providing commentary on 
drug-related news (as favoured by the World Federation 
Against Drugs) and using social media like blogs, Facebook 
and Twitter to influence drug discourses and disseminate 
information. The European Drug Policy Initiative (EDPI), a 
project established by the Hungarian Civil Liberties Union 
(HCLU), for example, used innovative videos to promote 
debate and influence public opinion.
In addition to seeking to secure support for their cause, 
public policy advocates placed a great deal of emphasis 
on networking, on working collaboratively and exchanging 
knowledge with like-minded groups. As a result, a complex 
web of connections was found between the policy actors 
grouped at similar ends of the advocacy orientation 
continuum (see Figure 2). For example, at the control 
reinforcement and use reduction end of the continuum, IOGT 
International and the Foundation for a Drug-Free Europe 
(FDFE) were members of the World Federation Against 
Drugs (WFAD). At the control reduction end, the International 
Drug Policy Consortium (IDPC) had originated at a meeting 
established by the Beckley Foundation. The IDPC’s members 
included the Beckley Foundation, Transform Drug Policy 
Foundation, Transnational Institute, Eurasian Harm Reduction 
Network (EHRN), Correlation Network and Diogenis, with 
the latter also working collaboratively with the Transnational 
Institute. In the harm reduction field, EHRN and Euro HRN are 
effectively regional branches of Harm Reduction International 
(HRI). Both organisations were established at international 
harm reduction conferences to bring together advocates 
in their respective areas. In addition, the directors of HRI 
had founded the International Centre on Human Rights and 
Drug Policy.
Alongside these networks, there were many funding linkages 
between these organisations. For example, several had 
connections to the philanthropic Open Society Institute, which 
funds groups advancing public health and human rights 
among marginalised communities. This is evident in the work 
of Eurasian HRN, EDPI, IDPC and the Transnational Institute. 
Policy actors along the advocacy continuum targeted and 
forged organisational relationships with a broad range 
of stakeholders. These included EU and UN institutions, 
policymakers, civil and public servants, social partners, public 
commentators and other relevant actors, in order to promote 
dialogue and connect policy, practice and research. 
All of the organisations operating at European or international 
level focused on using ‘insider strategies’ (Carbert, 2004) to 
lobby and influence service provision and legislation. This 
was done by participating in, and/or making submissions 
to, the institutional mechanisms which facilitate civil society 
involvement in drug policy formation, albeit at a consultative 
level. At EU level, this involved the EU Civil Society Forum 
on Drugs, which included participants from Correlation, 
Diogenis, ENCOD, Eurasian HRN and EURAD. Consultative 
status with the Economic and Social Council (ECOSOC) 
of the United Nations was held by Dianova International, 
Diogenis, Eurasian HRN, FAD, HRI, IOGT International and 
Transform Drug Policy Foundation. The following were 
members of the Vienna NGO Committee on Narcotic Drugs: 
the Beckley Foundation, IDPC, ENCOD, Transform Drug Policy 
Foundation, Transnational Institute, Dianova International, 
EURAD, Foundation for a Drug-Free Europe (FDFE), European 
Cities Against Drugs (ECAD), IOGT International, World 
Federation Against Drugs (WFAD). 
FIGUre 2
The continuum of policy advocacy orientation 
Control 
reduction
Harm 
reduction
Use 
reduction
Control 
reinforcement
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At the public policy advocacy level, research and building 
an evidence base were identified as central components of 
the work of almost all of the organisations. In this respect, 
the Beckley Foundation, the International Drug Policy 
Consortium and the Transnational Institute were particularly 
prolific in undertaking, commissioning and publishing original 
research, and in providing ‘rational’ and ‘objective’ evidence 
to inform effective drug policies. In contrast, advocacy actors 
at the ‘control reinforcement’ and use reduction end of the 
continuum focused on collating and disseminating research 
that illustrated the dangers of drugs to individuals, families and 
society. These latter actors also placed considerable emphasis 
on information-based prevention with young people and in 
schools; an example is FAD (Fundación de Ayuda contra la 
Drogadicción, Foundation Against Drug Addiction) in Spain.
Legal advocacy and a concern with human rights were recurring 
themes among the policy actors. However, differences existed 
between them. For example, some harm reduction organisations 
took a human-rights based approach to their work, and cited the 
rights of drug users to health and medical care enshrined in the 
UN Charter. In contrast, IOGT International argued that drugs 
constituted a threat to the dignity and freedom of people — 
rights also enshrined in the UN Charter — while the World 
Federation Against Drugs cited a moral, rather than legal, right 
of people to live in a drug-free world. 
Legal advocacy tools were used in a proactive way by several 
organisations. The International Centre on Human Rights 
and Drug Policy sought to make a case for reconciling the 
international narcotics control conventions with international 
human rights law. Through its Global Initiative for Drug Policy, 
the Beckley Foundation used legal advocacy to demonstrate 
how the UN drug control conventions could be rewritten to 
allow needs-based domestic drug policies. Actors concerned 
with maintaining the status quo of drug control legislation, 
such as European Cities Against Drugs (ECAD) and Europe 
Against Drugs (EURAD), focused on monitoring trends in 
national and European legislation to highlight and oppose 
loopholes that facilitated the sale and use of ‘legal highs’ 
and the operation of ‘head shops’, ‘coffee shops’ and drug 
consumption rooms.
In terms of their constituency base, control reduction and harm 
reduction actors mainly advocated on behalf of people using 
drugs. Use reduction and control reinforcement organisations, 
on the other hand, mainly advocated on behalf of the wider 
society and, in particular, young people and families.
Taken together, the analysis of these advocacy organisations 
highlights several themes. Organisations advocating for 
a reduction in drug controls focused on the perceived 
ineffectiveness of current global drug policy with regard to 
the crime, violence and corruption that it engendered; and 
the human rights derogations that have occurred as a result. 
They espouse a worldview in which most drug-related harm 
is caused by prohibition, rather than drug use, and they seek 
to evolve policy options ranging from the decriminalisation 
of possession offences to the regulation of drugs such as 
cannabis (for example, the Beckley Foundation) and the 
establishment of cannabis and cocoa leaf social clubs (6) 
(such as ENCOD). Harm reduction advocates were closely 
allied to those advocating control reduction through 
collaborative linkages, as described above, though the main 
focus of these groups was on service reform. Stemming from 
public health concerns with HIV/AIDS in the 1980s and 1990s, 
these organisations focused mainly on access to services and 
service user involvement in decision making on their treatment 
from a rights-based perspective.
Advocates of use reduction focused on drug education, 
prevention and abstinence or drug-free recovery. As 
observed earlier, in countries such as Spain, harm and use 
reduction actors operate side by side in service delivery and 
development. However, in other countries and at the European 
or international policy level, a dichotomy and a tension could 
be observed between both positions. 
Those advocating drug control reinforcement sought a drug-
free world and the eradication of drug use through education 
and law enforcement. Organisations promoting this position, 
such as the World Federation Against Drugs, emphasised the 
protective aspects of prohibition with regard to preserving 
traditional value systems and family life. The key themes 
emerging from this policy constellation were that drugs 
destroy lives, and that children, adolescents and families 
should be protected.
I  Conclusions
As the landscape of drug policy has changed and expanded 
from its historical origins, so too has the nature of advocacy 
in this policy area. New forums and media have emerged for 
representing and communicating the positions of advocacy 
groups seeking to shape drug policy. There are more channels 
available for making a direct input into the policy process 
through, for example, participation in consultative forums, as 
well as the submission of policy proposals, at the national, 
EU and international levels. In addition, the advancement 
of electronic communication methods has facilitated the 
publication of reports and policy briefings, the maintenance of 
an online presence through websites and social media, and an 
engagement with print, radio and television. All of these have 
contributed to a more rapid, organised and impact-oriented 
form of drug policy advocacy.
(6) cannabis social clubs are non-commercial organisations that organise the 
cultivation of limited amounts of cannabis for the personal needs of club 
members. clubs are currently active in Germany, the Netherlands and spain.
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At one level, advocacy organisations can be classified as 
belonging to civil society. Yet, a variety of non-state, not-for-
profit, third sector organisations with different institutional 
capacities, structures and focus operate within this space for 
collective action between the state and the market. Advocacy 
communities consist of a range of individuals and groups 
including those driven by personal, family and community 
experiences of drugs, those that act on the basis of insights 
gained from research and activists motivated by ideals of 
social justice. In addition, several contexts influence the 
positions adopted by these organisations. These include the 
prevailing local norms regarding drug use, drug control and 
regulation, local levels of law enforcement, and the models 
of welfare provision that shape the availability and practice of 
services addressing drug use and drug-related harms.
Through exploring the website-based presence of over two 
hundred drug policy advocacy organisations, this study 
provides an insight into the policy actors which were identified 
as operating within this contemporary advocacy sphere. These 
organisations are engaged in a process of targeted activities, 
which are undertaken with a view to influencing the attitudes 
and opinions of the public and policymakers about changing or 
maintaining the ethos and availability of drug service provision, 
and/or changing or maintaining national and international 
drug controls. These processes were seen to be grounded 
in aspirations for an improvement in the well-being of the 
individuals, groups or societies affected by drug use.
The majority of the 218 advocacy organisations identified 
in this study operate at the national level (69 %), with about 
one-tenth (14 %) having a European or international sphere of 
activity. Among these, three main types of organisations were 
found: civil society associations (32 %); NGOs or third sector 
organisations (32 %); and alliances, coalitions or networks of 
existing organisations (26 %). Their objectives and orientations 
were either in the area of service and practice development 
(both harm reduction (39 %) and use reduction (26 %)), or 
of drug control legislation (both control reduction (23 %) and 
control reinforcement (12 %)).
Overall, almost half of the advocacy organisations (48 %) were 
involved in public policy ‘cause’ advocacy. One-third (34 %) 
were concerned with professional ‘case’ advocacy, while the 
smallest grouping of advocacy organisations (16 %) conducted 
‘self’ or ‘peer’ advocacy. 
Advocacy organisations used a set of tools and strategies 
to communicate their positions and to influence policy and 
practice. Among the most common methods used were 
participation in media debates and social media sites (such 
as blogs, Facebook, Twitter) to raise awareness, influence 
dialogue and disseminate information. Lobbying at the 
national, EU or UN levels through policy submissions, petitions 
and policy forums plays an important role, as does information 
dissemination though participation in education, training, 
seminars and conferences. Traditional activist strategies, 
such as demonstrations and marches, were used by a small 
proportion of organisations. This may reflect, in part, the 
increased scope for engagement with policymakers and for 
communicating policy positions through modern technology. 
A small number of public policy advocacy organisations 
operated at the EU or international level (19). These 
organisations are influential in shaping drug policy discourses. 
Over one-third of these (36 %) advocated for a reduction in 
drug controls, one-quarter (26 %) supported harm reduction, 
one-fifth (21 %) promoted use reduction, and the remaining 
15 % called for the reinforcement of drug control legislation. 
Their primary advocacy focus on legislative change and the 
reduction of drug controls differed from the orientation of 
advocacy organisations as a whole, whose primary concern 
was with practice development and harm reduction. These 
positions reflect the focus of public policy advocacy in general 
(as distinct from professional and peer advocacy) and the 
current discourses on drug control reform at both European 
and international levels.
Changes in the nature, methods and impact of advocacy in 
the drugs area are evolving against a backdrop of ongoing 
economic and financial problems in the European Union. As 
drug services and law enforcement agencies come under 
increased financial pressure, it is likely that the number and 
type of policy actors engaged in advocacy will grow. Equally, as 
communities affected by drug problems experience renewed 
difficulties in providing services, an increased impetus to 
engage in advocacy may emerge. One way in which this may 
affect the practice of advocacy, is to shift more organisations 
towards the use of free social media tools to engage in 
dialogue and disseminate information. These easily accessible 
and rapid media tools offer a level of ‘voice’ that was previously 
difficult and resource-heavy to acquire and sustain. It will 
remain to be seen if information technology-based advocacy, 
as opposed to more traditional methods, such as insider 
advocacy strategies targeted at the institutional spaces where 
drug policy is discussed, will provide the means for shaping 
policy and service provision in the future.
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I  Annex
Table a1
Summary of characteristics of advocacy organisations by advocacy type
Advocacy type (number and percentage of organisations)
Peer (36, 17 %) Professional (76, 35 %) Public policy (106, 49 %)
Organisation type civil society association (58 %) NGO or third sector (57 %) civil society association (45 %)
User group (19 %) alliance, coalition, network (29 %) alliance, coalition, network (28 %)
alliance, coalition, network (14 %)
professional or representative body 
(13 %)
NGO or third sector (22 %)
NGO or third sector (9 %) User group (1 %) User group (3 %)
professional or representative body (2 %)
Scope National (67 %) National (71 %) National (70 %)
local or regional (25 %) local or regional (19 %) european or international (18 %)
european or international (8 %) european or international (11 %) local or regional (12 %)
Constituency all drug users (39 %) all drug users (47 %) Wider society (52 %)
Families of drug users (31 %) Wider society (37 %) all drug users (25 %)
Wider society (17 %) marginalised users (11 %) cannabis users (18 %)
people living with HIV/aIds (8 %) Families of drug users (4 %) marginalised users (2 %)
cannabis users (6 %) people living with HIV/aIds (1 %) medicinal cannabis users (2 %)
Families of drug users (1 %)
people living with HIV/aIds (1 %)
Main advocacy tools awareness raising (92 %) awareness raising (66 %) awareness raising (91 %)
lobbying (44 %) education and training (61 %) lobbying (52 %)
education and training (44 %) lobbying (57 %) education and training (35 %)
activism (17 %) research and publications (40 %) research and publications (35 %)
legal advocacy (6 %) legal advocacy (4 %) activism (13 %)
research and publications (3 %) activism (3 %) legal advocacy (4 %)
Advocacy orientation Harm reduction (44 %) Harm reduction (63 %) control reduction (40 %)
Use reduction (25 %) Use reduction (36 %) Use reduction (21 %)
control reduction (22 %) control reinforcement (1 %) control reinforcement (20 %)
control reinforcement (8 %) Harm reduction (20 %)
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Table a2
Drug policy advocacy organisations by country of location
Country (number  
of organisations) 
Name of organisation
Austria
(3)
elternkreis Wien (Verein zur Förderung der selbsthilfe für angehörige von suchtkranken)
ÖVdF (Österreichischer Verein für drogenfachleute)
Verein ‘starke süchtige’ (association of ‘strong addicts’)
Belgium
(8)
eNcOd (european coalition for Just and effective drug policies)
eUrad (europe against drugs)
european Federation of Therapeutic communities 
european public Health alliance
FdFe (Foundation for a drug-Free europe)
Fédération des Étudiants libéraux
modus Vivendi
Trekt uw plant vzw (cannabis social club)
Bulgaria
(6)
adaptation association 
better mental Health Foundation
Index Foundation
Initiative for Health Foundation
plovdiv (mothers against drugs)
Varna (association of parents ‘stop drugs’)
Croatia
(1)
Terra
Czech Republic
(7)
Konopí je lék, edukativní Konopí Klinika (cannabis is a cure, educational cannabis clinic)
legalizace.cz
Občanské sdružení Konopa (civic association Hemp) 
Občanské sdružení Vlastenecká Fronta (civic association patriotic Front)
Občanské sdružení Změňpolitiku.cz (civic association change the policy)
rezidenti Na skalce proti drogám (residents on Na skalce street against drugs)
Vlastenecký Klub (civil association patriotic club)
Denmark
(4)
danish society for addictive medicine 
bruger Foreninger (drug Users Union)
Gadejuristen (streetlawyers)
National association of Families to drug Users 
Finland
(11)
a-Klinikkasäätiö (a-clinic Foundation)
ehkäisevä päihdekyö eHYT rY 
elämäntapaliitto ry (association for Healthy lifestyles)
Finnish cannabis association (Fca)
Huumeboikotti 
Irti Huumeista ry (Free From drugs)
Nordic alcohol and drug policy Network (NOrdaN)
sOsTe (suomen sosiaali ja terveys ry, Finnish society for social and Health)
stop Huumeille rY
Turun seudun Kannabisyhdistys (Turku cannabis association)
Yad (Youth against drugs rY)
continues on next page
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Table a2 (cONTINUed)
Country (number  
of organisations) 
Name of organisation
France
(23)
18 Joint
act Up-paris
aFr (association française de réduction des risques, French harm reduction association)
aIdes
association Vigilance
asUd
caaT (conseils aide et action contre la Toxicomanie)
c’est quoi la drogue
cNId (comité National d’Information sur la drogue)
drogue danger débat
enfance sans drogue
Fédération addiction
FNapT (la Fédération Nationale des associations de prévention Toxicomanie)
Free cannabis 
Jeunesse sans drogue
Ks Keep-smiling
l’aNpaa (l’association Nationale de prévention en alcoologie et addictologie) 
l’association Nationale edVO (l’espoir du Val d’Oise)
le phare
marche mondiale du cannabis 
parents contre la drogue
réseau Français de réduction des risques (rdr)
stop à la drogue
Germany
(13)
akzept e.V. 
bundesverband der eltern und angehörigen für akzeptierende drogenarbeit e.V. (accepting parents) 
cannabislegal.de
dHs (German centre for addiction Issues)
dHV (deutscher Hanf Verband)
dJV (deutscher Jugendschutz-Verband)
FVs (Fachverband sucht e.V., German council on alcohol and addiction)
German society of addiction medicine
Hanfparade 
INdrO e.V. 
Jes bundesverband (Junkies, ehemalige, substituierte)
schildower Kreis
Verein für drogenpolitik e.V. 
Greece
(2)
diogenis (drug policy dialogue in south east europe)
pyxida
Hungary
(5)
european drug policy Initiative (edpI)
Hungarian civil liberties Union (HclU)
Kendermag egyesület (Hemp seed association)
madÁsZsZ (magyar drogprevenciós és artalomcsökkentö szervezetek szövetsége, association of Hungarian 
Organisations for drug prevention and Harm reduction)
maT (magyar addiktológiai Társaság, Hungarian association of addictology)
continues on next page
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Table a2 (cONTINUed)
Country (number  
of organisations) 
Name of organisation
Ireland
(11)
ana liffey drug project
ballymun Youth action project
citywide drugs crisis campaign 
Family support Network
IcON (Inner city Organisations Network) 
INeF (Irish Needle exchange Forum) 
Irish penal reform Trust 
Jesuit centre for Faith and Justice 
merchants Quay Ireland (mQI)
saOl
UIsce (Union for Improved services, communication and education) 
Italy
(4)
associazione Osservatorio droga 
associazione per la cannabis Terapeutica (acT)
eUrOpad (european Opiate addiction Treatment association)
san patrignano
Latvia (1) dIa+lOGs
Lithuania
(5)
demeTra (association of HIV affected women and the family)
eurasian Harm reduction Network (eHrN)
Galiu Gyventi
labdaros ir paramos fondas Krizių prevencijų centras 
mentor lietuva (mentor lithuania)
Netherlands
(7)
de regenboog Groep 
landelijke stichting Ouders en Verwanten van drugsverslaafden (Foundation of parents and relatives of drug addicts)
mainline
stichting drugs beleid (Netherlands drug policy Foundation) 
stichting legalize! (legalise Foundation)
Transnational Institute (drugs and democracy) 
Verbond Voor Opheffing van het cannabisverbod (association for the abolition of cannabis prohibition)
Norway
(4)
actis (Norwegian policy Network on alcohol and drugs)
Fagrådet (council on alcohol and drug problems in Norway)
Forbundet mot rusgift (Fmr, league against intoxicants — lIa)
lms (landsforbundet mot stoffmisbruk)
Poland
(4)
mONar
polska sieć polityki Narkotkyowej (pspN, polish Network on drug policy) 
powrót Z U (association of parents of addicts)
stowarzyszenie na rzecz racjonalnej i efektywnej polityki Narkotykowej KaNaba (association on rational and effective 
drug policy KaNaba)
Portugal
(4)
apdes (agência piaget para o desenvolvimento)
associação para um portugal livre de drogas
GaT (Grupo português de activistas sobre Tratamentos de VIH/sIda)
marcha Global da marijuana lisboa (mGm lisboa)
Romania
(6)
alIaT (alliance for fighting against alcoholism and drug addiction)
FIc (Foundation for community care services)
Integration
romanian Harm reduction Network
rOsaac (romanian substance abuse and addiction coalition)
stichting romanian children’s Humanitarian Foundation 
continues on next page
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Table a2 (cONTINUed)
Country (number  
of organisations) 
Name of organisation
Slovenia
(3)
drogart
project Konoplja.org
Zveza društer na področju drog v sloveniji 
Spain
(31)
abd (asociación bienestar y desarrollo)
acp (asociación civica para la prevención)
adaFad
alUcOd (la asociación de lucha contra las drogas)
apriacyl 
asociación andaluza de profesionales en drogodependencias (aprOda)
asociación cannabica Valenciana 
asociación contra la droga clara maria 
asociación de entidades de centros de día de dependencias (asecedI)
asociación de deportistas contra la droga (adcd)
asociación Vieriro
cañamo
dianova International
edeX
Fad (Foundation against drug addiction)
Federación andaluza eNlace
Federación de asociaciones cannabicas (Fac)
Fundación atenea Grupo GId
Fundación Galega contra O Narcotráfico
Fundación salud y communidad
Fundación Vivir sin drogas
Hegoak
IreFrea (european Institute of studies on prevention)
JIra (la juventud independentista revolucionaria andaluza)
la Huertecica 
Niños y padres contra la droga (NYpacOld)
plataformavecinal
políticas de drogas y sostenibilidad
proyecto Hombre 
socidrogalcohol 
UNad (Unión de asociaciones y entidades de atención al drogodependiente) 
Sweden
(12)
european cities against drugs (ecad)
Föräldraföreningen mot Narkotika (FmN, parents association against drugs)
IOG-NTO
IOGT International
KsaN (WOcad, Women’s Organisation committee on alcohol and drug Issues)
rFHl (National association for aid to drug abusers)
rNs (riksförbundet Narkotikatritt samhäile, swedish National association for a drug-Free society)
slaN (sveriges landsräd för alkohol och- narkotikafrögor, The swedish Youth council on alcohol and drugs)
sImON (svenskar och Invandrare mot Narkotika, swedes and Immigrants against Narcotics)
sNpF (svenska Narkotika polisföreningens Hemsidd, swedish Narcotics Officers association)
svenska brukarföreningen (swedish drug Users Union)
World Federation against drugs
continues on next page
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Table a2 (cONTINUed)
Country (number  
of organisations) 
Name of organisation
United Kingdom
(40)
action on addiction
addaction 
addiction recovery Foundation (arF)
adfam (Families, drugs and alcohol)
beckley Foundation
clear: cannabis law reform
correlation Network
drug education Forum
drug equality alliance (dea)
drugscope
eata
euro HrN (european Harm reduction Network)
Free casey
Harm reduction International
Independent scientific committee on drugs
International centre on Human rights and drug policy
International doctors for Healthy drug policies
International drug policy consortium 
International Network of people who Use drugs (INpUd)
Know drugs
london drug and alcohol Network (ldaN)
methadone alliance 
National Needle exchange Forum UK
parents against lethal addictive drugs (palad)
positive prevention plus (formerly National drug prevention alliance)
re:vision drug policy Network
release
re-solv
scottish drugs Forum
scottish Families affected by drugs
society for the study of addiction (ssa)
students for sensible drug policy UK
The Hempire 
The UK cannabis Internet activist (UK cIa) 
Transform drug policy Foundation
Turning point
UK drug policy commission (UKdpc)
UK Harm reduction alliance (UKHra)
Women’s Harm reduction International Network (WHrIN)
Youth rIse (resource Information support education)
No country specified
(3)
euronet (european Network for practical approaches in addiction prevention)
Norden mot Narkotik (NmN, Nordic countries against drugs)
rome consensus for a Humanitarian drug policy
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